New antibody drugs aim to prevent Catheter-Related blood clots

NCT ID NCT07697599

Not yet recruiting Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests two experimental drugs, REGN7508 and REGN9933, to see if they can prevent blood clots in people who have a peripherally inserted central catheter (PICC). People with PICCs are at higher risk for venous thromboembolism (VTE), which can be serious. The trial compares these drugs against a placebo to evaluate their effectiveness and safety, including any risk of bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN7508 (cenvacibart) and REGN9933 (amrecibart), monoclonal antibodies against factor XI
What this could lead to: If successful, these drugs could offer a new way to prevent dangerous blood clots in people who need a central catheter, potentially reducing the risk of serious complications like pulmonary embolism.
What could go wrong: This is an early-phase trial, and the drugs may not prove more effective than placebo. There is also a risk of unexpected bleeding or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates